JP Morgan Chase’s Aligos Therapeutics ALGS Stock Holding History
Bought
Maintained
Sold
Other funds holding ALGS
DTC
SCM
VCM
WP
SC
BBA
JP Morgan Chase's ALGS Position: Q1 2026 in Review
JP Morgan Chase increased its Aligos Therapeutics (ALGS) stake by 120% in Q1 2026, buying an estimated $2.79K and bringing the position to 674 shares worth $4.42K. The position accounts for ﹤0.01% of the portfolio, ranked #6904.
JP Morgan Chase first reported a position in ALGS in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.1M in Q4 2020. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.
- JP Morgan Chase held 674 shares of Aligos Therapeutics worth $4.42K as of Q1 2026.
- JP Morgan Chase bought 368 Aligos Therapeutics shares in Q1 2026, an estimated $2.79K.
- Aligos Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6904 holding.
- JP Morgan Chase first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 22 quarters since.
- JP Morgan Chase's Aligos Therapeutics position peaked at $1.1M in Q4 2020.
- 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.